Clinical Trials at Avadel Pharmaceuticals

Micropump® Sodium Oxybate

Sodium Oxybate is currently the only drug approved for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients suffering from narcolepsy. To achieve effective relief of symptoms, sodium oxybate is typically dosed twice nightly – once at bedtime and again 2.5 – 4 hours later.

Avadel’s Micropump®-based formulation of sodium oxybate, FT218, for one single dose before bedtime has the potential to provide patients not only more convenience but could also provide benefit by eliminating or reducing the current disruption in nighttime sleep. The potential for additional benefits of FT218, including improved safety, are being evaluated in the company’s REST-ON Phase III clinical trial. Further details of the study can be found online.

For more information on narcolepsy can be found by visiting www.narcolepsynetwork.com.